SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Podcast
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director Vinay Prasad reveal new COVID-19 vaccine strategy following Novavax approval; ODAC underway after chaotic planning; more.
May 21, 2025
 · 
2 min read
 · 
Heather McKenzie
Conversion creative ideas into money with innovation machine, startup opportunity to earn money by motenization. Light bulbs in funnel converts to coins flowing through tap cartoon vector illustration
Venture capitalists
The Top 5 Most Active Corporate VCs in Pharma
BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made headlines last year with its $16.5 billion Catalent buy, topped the list.
May 21, 2025
 · 
5 min read
 · 
Annalee Armstrong
Metal pipe with empty flange covering the end. A PVC pipe with metal joins and flanges with bolts.
Opinion
Evolving Market Pressures Force Biopharma Companies to Cut Assets Early
From a higher bar for regulatory clearance to pricing limitations, drug development is more expensive than ever. This has led firms to make tough pipeline decisions early in the development process. The result may be costly for all of us.
May 21, 2025
 · 
5 min read
 · 
Michael N. Abrams
FDA
FDA’s New Risk-Based Approach to COVID-19 Vaccines Aims to Ease ‘Public Distrust’: Makary, Prasad
The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination trends.
May 20, 2025
 · 
4 min read
 · 
Heather McKenzie
3d pharmaceutical world icon with included clipping path.
Drug pricing
New Details From Trump’s Drug Pricing Effort Put Branded Drugs in the Crosshairs
Drugmakers will be expected to commit to aligning U.S. prices with the lowest price set in a group of peer nations for all brand products across all markets that do not currently have generic or biosimilar competition.
May 20, 2025
 · 
1 min read
 · 
Annalee Armstrong
Abstract colorful DNA helix held by two hands, symbolizing genetics, biology, and advancements in medical research. Conceptual art design. Concept of medicine, treatment, health care, medical science
Rare diseases
CRISPR Success in Single Baby Highlights Rare Disease ‘Crisis’
Most of the 15 million children with a rare disease have no FDA-approved treatments available to them. And when it comes to the most-rare conditions, there isn’t even a pipeline.
May 20, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Exploration, Currency,Hiding,Discovery,Searching, Businessman
China
Pfizer’s China Deal Worth up to $6B Eclipses Peers in a Frenzied Market
The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially more than $4 billion.
May 20, 2025
 · 
1 min read
 · 
Annalee Armstrong
Blue pills and world globe on white background.
Opinion
Understanding What Trump’s MFN Executive Order Can and Can’t Do
The Most Favored Nation order is unlikely to deliver broad, sustained savings without triggering legal challenges, administrative friction and unintended consequences for both the healthcare sector and patient access.
May 20, 2025
 · 
6 min read
 · 
Robert Albarano
Handshake in retro collage style. Hands with halftone effect make a deal, a hand comes out of a laptop, online deals. Vector modern illustration.
Collaboration
CRISPR Expands Focus, Pays Up To $95M in Sirius’ siRNA Pact
The partnership with Sirius expands CRISPR Therapeutics’ modality toolkit, especially in the cardiovascular space.
May 20, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS